Association of homogeneous inflamed gene signature with a better outcome in patients with metastatic melanoma treated with MAGE-A3 immunotherapeutic

PURPOSE: This study assessed clinical activity, safety and immunogenicity of MAGE-A3 immunotherapeutic in patients with MAGE-A3-positive metastatic melanoma. PATIENTS AND METHODS: In this open-label, multicentre, uncontrolled, Phase II study (ClinicalTrials.gov NCT00896480), patients received ≤24 do...

Descripción completa

Detalles Bibliográficos
Autores principales: Baurain, Jean-François, Robert, Caroline, Mortier, Laurent, Neyns, Bart, Grange, Florent, Lebbe, Céleste, Ulloa-Montoya, Fernando, De Sousa Alves, Pedro Miguel, Gillet, Marc, Louahed, Jamila, Jarnjak, Silvija, Lehmann, Frédéric F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069918/
https://www.ncbi.nlm.nih.gov/pubmed/30094070
http://dx.doi.org/10.1136/esmoopen-2018-000384

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6069918/
https://www.ncbi.nlm.nih.gov/pubmed/30094070
http://dx.doi.org/10.1136/esmoopen-2018-000384

Ejemplares similares